Belimumab is a mAb that inhibits the soluble counterpart of the B-lymphocyte stimulator (BLyS), which is a key mediator of B-cell differentiation and survival, and thus dampens B-cell mediated autoimmunity [126,127]. The gene discussed is TNFSF13B; the disease is Autoimmunity.